# Bruce Robertson

> Bruce Robertson is a Series C investor at H.I.G. BioHealth Partners backing Health Care. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [H.I.G. BioHealth Partners](https://shizune.co/investors/profile/h-i-g-biohealth-partners)
- Total investments: 7
- Last investment: Jun 2023
- Lead investor: 43%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/bruce-robertson-853a95

Bruce Robertson is a Series C investor at H.I.G. BioHealth Partners focused on Health Care and Medical. As a Managing Director at H.I.G. BioVentures, Bruce focuses on investment opportunities in the life sciences sector, including biopharmaceuticals, medical devices, and diagnostics. Bruce currently serves on the boards of Apollo Endosurgery, CardioFocus, Cerephex, and Clarus Therapeutics.Bruce has been active in the life sciences sector for morethan 20 years. Prior to joining H.I.G., Bruce served most recently as Managing Director at Toucan Capital, an early-stage venture capital fund focusing on life science investments. While at Toucan, Bruce invested in leading drug and device companies throughout the U.S. Prior to Toucan, Bruce was a General Partner at GIV Venture Partners, a venture capital firm focused on early stage investments in the US, India, and China. Prior to his venture capital career, Bruce was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN's partnering and M&A strategies. Bruce started his career as a Research Manager at W.R. Grace & Co., focusing on medical devices.Bruce is on the boards of the Mid-Atlantic Venture Association, Adventist Healthcare, the University of Delaware Research Foundation, and the BioLife Fund of Virginia’s Center for Innovative Technology. Bruce holds a BSE in Chemical Engineering and BA in Mathematics from the University of Pennsylvania, a PhD in Chemical/Biomedical Engineering from the University of Delaware, and an MBA with High Distinction from Harvard Business School.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 43% |
| Medical | 2 | 29% |
| Therapeutics | 2 | 29% |
| Biotechnology | 2 | 29% |
| Medical Device | 2 | 29% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 29% |
| Funding Round | 2 | 29% |
| Series A | 1 | 14% |
| Series B | 1 | 14% |
| Series D | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Augmedics | Augmedics is a provider of augmented reality (AR) surgical image guidance solutions. Augmedics seeks to improve healthcare by developing cutting-edge technologies that will revolutionize surgical treatment. The company’s first product, the xvision-spine (XVS) system, is an augmented-reality surgical navigation system designed to allow surgeons tosee and navigate inside a patient’s body during complex procedures. | $82.5M | Series D | Jun 27, 2023 |  |
| Augmedics | Augmedics is a provider of augmented reality (AR) surgical image guidance solutions. Augmedics seeks to improve healthcare by developing cutting-edge technologies that will revolutionize surgical treatment. The company’s first product, the xvision-spine (XVS) system, is an augmented-reality surgical navigation system designed to allow surgeons tosee and navigate inside a patient’s body during complex procedures. | $36M | Series C | Mar 30, 2021 |  |
| Exagen | Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE brand, several of which are based onour proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus.Exagen was established in 2002 and is headquartered in Vista, California. | $22.6M |  | Jul 16, 2019 |  |
| Iconic Therapeutics | Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells. It is a biopharmaceutical company that has an exclusive license on issued Yale University patents for a novel recombinant protein called hI-con1. hI-con1 binds tissue factor (TF), triggering natural killer cells toselectively destroy pathologic neovascular blood vessels. Such cells include choroidal neovascularization (CNV) associated with wet age-related macular degeneration (wet AMD) and TF-expressing cancer cells and tumor-associated pathologic blood vessels (PBV). In addition to this cell-mediated cytotoxicity, hI-con1 may also interrupt the positive feedback loop between tissue factor and vascular endothelial growth factor (VEGF), thereby reducing VEGF levels. Phase 1 studies with hl-con1 are complete and no dose limited toxicities were observed. Evidence of dose-related biologic activity was observed. | $4.1M |  | Jun 15, 2018 |  |
| Iconic Therapeutics | Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells. It is a biopharmaceutical company that has an exclusive license on issued Yale University patents for a novel recombinant protein called hI-con1. hI-con1 binds tissue factor (TF), triggering natural killer cells toselectively destroy pathologic neovascular blood vessels. Such cells include choroidal neovascularization (CNV) associated with wet age-related macular degeneration (wet AMD) and TF-expressing cancer cells and tumor-associated pathologic blood vessels (PBV). In addition to this cell-mediated cytotoxicity, hI-con1 may also interrupt the positive feedback loop between tissue factor and vascular endothelial growth factor (VEGF), thereby reducing VEGF levels. Phase 1 studies with hl-con1 are complete and no dose limited toxicities were observed. Evidence of dose-related biologic activity was observed. | $10M | Series C | Aug 09, 2016 |  |
| Iconic Therapeutics | Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells. It is a biopharmaceutical company that has an exclusive license on issued Yale University patents for a novel recombinant protein called hI-con1. hI-con1 binds tissue factor (TF), triggering natural killer cells toselectively destroy pathologic neovascular blood vessels. Such cells include choroidal neovascularization (CNV) associated with wet age-related macular degeneration (wet AMD) and TF-expressing cancer cells and tumor-associated pathologic blood vessels (PBV). In addition to this cell-mediated cytotoxicity, hI-con1 may also interrupt the positive feedback loop between tissue factor and vascular endothelial growth factor (VEGF), thereby reducing VEGF levels. Phase 1 studies with hl-con1 are complete and no dose limited toxicities were observed. Evidence of dose-related biologic activity was observed. | $20M | Series B | Apr 16, 2014 |  |
| Cerephex | Cerephex is a company developing its proprietary RINCE technology for treatment applications involving noninvasive brain stimulation. Cerephex is currently engaged in development activities aimed at gaining FDA approval of its NeuroPoint device for the management of fibromyalgia, a chronic pain condition that involves abnormal central painprocessing mechanisms. | $5.9M | Series A | Oct 12, 2012 |  |

7 of 7 investments shown.

## Co-investors
- [Lundbeckfonden Ventures](https://shizune.co/investors/profile/lundbeckfond-ventures) — VC Fund, 3 deals together
- [MPM Capital](https://shizune.co/investors/profile/mpm-capital) — VC Fund, 3 deals together
- [Almeda Ventures](https://shizune.co/investors/profile/almeda-ventures) — VC Fund, 2 deals together
- [Revival Healthcare Capital](https://shizune.co/investors/profile/revival-healthcare-capital) — VC Fund, 2 deals together
- [Evidity Health Capital](https://shizune.co/investors/profile/canepa-advanced-healthcare-fund) — VC Fund, 1 deal together
- [CPMG](https://shizune.co/investors/profile/cpmg) — VC Fund, 1 deal together

## About H.I.G. BioHealth Partners

VC Fund · Miami, United States

H.I.G. BioVentures invests in a broad range of life science companies across multiple sectors and stages of development. Their seasoned investment team has extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer. They invest in companies developing novelproducts for significant unmet medical needs.

5 contacts available at H.I.G. BioHealth Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Bruce Robertson | Managing Director | https://shizune.co/investors/profile/bruce-robertson |
| Jorge Ramirez | Vice Presidents | https://shizune.co/investors/profile/jorge-ramirez-3 |
| Aaron Davidson | Managing Director | https://shizune.co/investors/profile/aaron-davidson |
| Michael Wasserman | Managing Director | https://shizune.co/investors/profile/michael-wasserman |
| Sami Mnaymneh | Co-Founder | https://shizune.co/investors/profile/sami-mnaymneh |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Bruce Robertson invest in?

Bruce Robertson invests primarily in Health Care, Medical and Therapeutics startups, most often at Series C and Funding Round stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Bruce Robertson last invest?

The most recent investment recorded for Bruce Robertson closed in Jun 2023. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co